Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Takeda Bags Global Rights to Protagonist’s Rare Hematology Asset
Takeda Pharmaceutical has snagged the global rights to develop and commercialize rusfertide, a late-stage asset of Protagonist Therapeutics being developed for rare chronic blood disorders. The companies struck a worldwide licensing and collaboration deal on January 31. Rusfertide is an…
To read the full story
Related Article
- US FDA Accepts Takeda’s Rusfertide Filing, Grants Priority Review
March 3, 2026
- Takeda Files Polycythemia Vera Drug Rusfertide in US
January 7, 2026
- Protagonist/Takeda’s Hematology Med Makes Mark in PIII
March 5, 2025
BUSINESS
- Kowa Wins Hong Kong Approval for Livalo, Glanatec OK in Vietnam
July 3, 2026
- Medinet Exercises Option for Stempeucel Rights in Japan
July 3, 2026
- Average Pay at 21 Japan Drug Makers Up 3.8%, Chugai Tops 13 Million Yen
July 2, 2026
- Mochida Seeks Pediatric Expansion for Urece
July 2, 2026
- Kowa Files US NDA for Nicox’s Glaucoma Drug
July 2, 2026
The number of newly listed generic drugs in Japan has fallen sharply over the past decade, reflecting structural changes in…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…